Publication:
Treating chronic hepatitis delta: the need for surrogate markers of treatment efficacy

Simple item page
dc.contributor.coauthorAbbas, Zaigham
dc.contributor.coauthorButi, Maria
dc.contributor.coauthorCornberg, Markus
dc.contributor.coauthorEsteban, Rafael
dc.contributor.coauthorEtzion, Ohad
dc.contributor.coauthorGanes, Edward J.
dc.contributor.coauthorGish, Robert G.
dc.contributor.coauthorGlenn, Jeffrey S.
dc.contributor.coauthorHamids, Saeed
dc.contributor.coauthorHeller, Theo
dc.contributor.coauthorKoh, Christopher
dc.contributor.coauthorLampertico, Pietro
dc.contributor.coauthorLurie, Yoav
dc.contributor.coauthorManns, Michael
dc.contributor.coauthorParana, Raymundo
dc.contributor.coauthorRizzetto, Mario
dc.contributor.coauthorUrban, Stephan
dc.contributor.coauthorWedemeyer, Heiner
dc.contributor.coauthorWranke, A.
dc.contributor.coauthorBorzacov, Pinheiro L. M.
dc.contributor.coauthorLobato, C.
dc.contributor.coauthorHamid, S.
dc.contributor.coauthorCeausu, E.
dc.contributor.coauthorDalekos, G. N.
dc.contributor.coauthorTurcanu, A.
dc.contributor.coauthorNiro, G. A.
dc.contributor.coauthorLubna, F.
dc.contributor.coauthorAbbas, M.
dc.contributor.coauthorIngiliz, P.
dc.contributor.coauthorFerenci, P.
dc.contributor.coauthorVanwolleghem, T.
dc.contributor.coauthorHayden, T.
dc.contributor.coauthorDashdorj, N.
dc.contributor.coauthorMotoc, A.
dc.contributor.coauthorHardtke, S.
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorYurtaydın, Süleyman Cihan
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-11-09T13:51:17Z
dc.date.issued2019
dc.description.abstractChronic hepatitis delta represents the most severe form of chronic viral hepatitis. The current treatment of hepatitis delta virus (HDV) infection consists of the use of interferons and is largely unsatisfactory. Several new compounds are currently in development for the treatment of HDV infection. However, surrogate markers that can be used to develop clinical endpoints in HDV infection are not well defined. In the current manuscript, we aimed to evaluate the existing data on treatment of HDV infection and to suggest treatment goals (possible "trial endpoints") that could be used across different clinical trials.
dc.description.fulltextYES
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue5
dc.description.openaccessYES
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipN/A
dc.description.versionPublisher version
dc.description.volume70
dc.identifier.doi10.1016/j.jhep.2018.12.022
dc.identifier.embargoNO
dc.identifier.filenameinventorynoIR01725
dc.identifier.issn0168-8278
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-85062155428
dc.identifier.urihttps://doi.org/10.1016/j.jhep.2018.12.022
dc.identifier.wos464016500023
dc.keywordsHepatitis D
dc.keywordsTreatment endpoints
dc.keywordsSurrogate marker
dc.keywordsNew treatment approaches
dc.language.isoeng
dc.publisherElsevier
dc.relation.grantnoNA
dc.relation.ispartofJournal of Hepatology
dc.relation.urihttp://cdm21054.contentdm.oclc.org/cdm/ref/collection/IR/id/8322
dc.subjectMedicine
dc.subjectGastroenterology and hepatology
dc.titleTreating chronic hepatitis delta: the need for surrogate markers of treatment efficacy
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorYurtaydın, Süleyman Cihan
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
8322.pdf
Size:
547.77 KB
Format:
Adobe Portable Document Format
Download

Collections

Publications with Fulltext